00:35 , Nov 30, 2016 |  BC Extra  |  Company News

Arrowhead prunes pipeline over toxicity concerns

Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) sank $2.63 (60%) to $1.76 in early after-hours trading after it said will discontinue development of all programs using its EX1 liver-targeted, IV delivery vehicle for its RNA therapies. The cuts...
07:00 , Jun 2, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Factor XII

Autoimmune disease INDICATION: Multiple sclerosis (MS) Patient sample and mouse studies suggest inhibiting Factor XII could help treat MS. In patient plasma samples or in mouse lymph nodes from the experimental autoimmune encephalomyelitis (EAE) model of MS,...
08:00 , Nov 9, 2015 |  BC Week In Review  |  Company News

Dyax, Shire deal

Shire will acquire Dyax for $37.30 per share, or $5.9 billion in cash. The price represents a 35% premium to Dyax’s close of $27.53 on Oct. 30, the last trading day before the deal was...
01:15 , Nov 3, 2015 |  BC Extra  |  Top Story

Shire builds on HAE franchise with Dyax takeout

Shire plc (LSE:SHP; NASDAQ:SHPG) will acquire Dyax Corp. (NASDAQ:DYAX) for $37.30 per share, or $5.9 billion in cash. The price represents a 35% premium to Dyax's close of $27.53 on Oct. 30, the last trading...
08:00 , Feb 27, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cardiovascular disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cardiovascular disease Blood coagulation Factor XII Mouse and rabbit studies suggest an anti-factor...
08:00 , Feb 27, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cardiovascular disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cardiovascular disease Blood coagulation Factor XI; factor XII Rabbit studies suggest antisense...
08:00 , Feb 27, 2014 |  BC Innovations  |  Targets & Mechanisms

The XII factor

Factor XII sits atop one branch of the clotting cascade but has not been pursued for treating and preventing thrombosis because it was seen as a minor player in blood coagulation. Now, a group from...
07:00 , Oct 15, 2009 |  BC Innovations  |  Distillery Therapeutics

Indication: Cardiovascular disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cardiovascular disease Arterial thrombosis; venous thromboembolism (VTE) ...
08:00 , Nov 10, 2008 |  BC Week In Review  |  Clinical News

Recombinant coagulation Factor XIII: Phase III started

In August, Novo began an open-label, international Phase III trial of intravenous rh FXIII in 40 patients. Novo licensed the product from ZymoGenetics in 2004 (see BioCentury, Oct. 11, 2004). ZymoGenetics Inc. (NASDAQ:ZGEN), Seattle, Wash....
07:00 , Sep 25, 2008 |  BC Innovations  |  Targets & Mechanisms

New Roles for Old Factor

Researchers at the University Medical Center Utrecht and Crossbeta Biosciences B.V. have linked high levels of activated Factor XII with amyloidosis, a metabolic disease that is characterized by misfolded protein aggregates.1 The company plans to...